Navigation Links
Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations

- Lead Clinical Program and Two Clinical Candidates Featured -

SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, announced four abstracts have been selected for presentation at the meeting of American Association for Cancer Research being held in San Diego on April 12-16, 2008.

"We are pleased to have this opportunity to present important data on both RAV12, Raven's lead therapeutic antibody entering Phase 2 development for the treatment of adenocarcinomas and the promising near-term clinical candidates in our oncology pipeline," stated George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "Raven will present significant new data on RAV12 supporting the chemotherapeutic synergies that inform its impending phase 2 trials. In addition, recent discoveries concerning novel epitopes and effector mechanisms associated with two new antibodies targeting cancer stem cells will be presented for the first time. Both antibodies are slated for clinical development. Finally, having advanced the technology to culture cancer stem cells on a sustained basis in vitro, we will present their in vivo biology, using prostate cancer stem cells as an important new model system for understanding the growth and metastasis of human cancer."

The presentations are scheduled as follows:

Oral Presentation in a Minisymposium Session

The anti-B7-H3-4Ig antibody TES7 recognizes cancer stem cell lines, modulates angiogenic factor secretion, and exhibits potent anti-tumor activity in vivo

Session ID: Experimental and Molecular Therapeutics 24

Date and Time: Monday, April 14, 2008, 1:00 PM

Abstract Number: 2555

Poster Sessions

Human prostate cancer stem cell line spontaneously metastasizes in vivo

Session ID: Tumor Biology 5

Date and Time: Sunday, April 13, 2008, 8:00 AM

Abstract Number: 385

The RAV12 monoclonal antibody mediates antitumor activity via multiple mechanisms of action and synergizes with chemotherapeutic agents in vivo
Session ID: Experimental and Molecular Therapeutics 32

Date and Time: Tuesday, April 15, 2008, 8:00 AM

Abstract Number: 4000

Monoclonal antibody KID24 targets human ADAM9 and is a potent inhibitor of tumor growth and metastasis in vivo
Session ID: Experimental and Molecular Therapeutics 32

Date and Time: Tuesday, April 15, 2008, 8:00 AM

Abstract Number: 3989

About Raven

Raven biotechnologies, inc. ( is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (Pink Sheets: VXGN), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected to create a drug development company with a robust pipeline of monoclonal antibody candidates in oncology, proprietary antibody discovery platforms, biopharmaceutical manufacturing capabilities and sufficient cash to fund operations at least through the end of 2009. The merger is expected to close in the first half of 2008.

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Amyris Biotechnologies Announces $70 Million Series B Round
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):